UnitedHealth Group (UNH) says its revenue this year will increase by $2 billion more than earlier projected for 2015 thanks in part to its expansion on public exchanges under the Affordable Care Act and its push to more value-based care contracts with doctors and hospitals. The outlook, which includes increased earnings projections for this year […]
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Pharma continues to lag behind the consumer space in the use of mobile marketing technologies, but the steady advance of consumer tech giants Google and Amazon into the healthcare space means that the industry will have to adapt the tools of AI, voice and chatbots into their marketing, just as their consumer brethren already have.
Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.
In the initial excitement over the possibilities of mobile marketing, pharma rushed to create its own apps. And then these apps languished.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Augmented reality (AR) gained widespread attention the summer of 2016 with the addictive game Pokémon Go. But these days, AR is not just for fun. This disruptive technology is expected to drive significant changes to businesses across many industries because of its ability to combine the virtual and physical worlds.
Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Pharma marketers must listen to their customers and find ways to smooth the patient journey if they are to create effective customer experiences and create loyalty beyond the first prescription.
Consumer/Patient Experience Special Feature: Digital therapeutics – Improving the patient experience at scale
It’s no surprise that the patient experience with the healthcare system often leads to frustration and despair. With chronic disease affecting around 50 percent of the U.S. population, it puts into perspective the sheer volume of patient experiences that are being generated each day and the magnitude of the problems that need solving. The high cost of therapies, the long wait to see a physician, the administrative burden of getting a prior authorization…the list goes on. But the day is coming, and in some cases it’s already here, where a patient could have a robust health system right in their pocket.
Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know
Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
BERKELEY, Calif.–(BUSINESS WIRE)–Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial […]
April 14, 2015By Mark Terry, BioSpace.com Breaking News Staff Bayer HealthCare, a division of Germany-based Bayer AG (BAYZF), announced today that it will spend $100 million to expand its facilities near its campus in East Bay San Francisco. The new building will be 80,000-square-feet in size and will replace an older facility. The new build […]
GlaxoSmithKline (GSK) said Rowex Ltd is preparing to sell a product similar in its packaging to the “Seretide” inhaler and that this infringed its trademark. Seretide is the fourth-highest-selling pharmaceutical product in the world, with more than $62bn (€58bn) in global sales, including Ireland. The UK-based Glaxo Group, along with GSK (Ireland) Ltd, trading as […]
(Reuters) – Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move — quite literally. As of last month, a four-days-a-week service set up by the drugmaker with Sun Air is connecting staff in its new Cambridge science and operations hub with […]
The continued climb of the U.S. dollar weighed heavily on pharmaceutical giant Johnson & Johnson’s first quarter earnings reported Tuesday morning. It was in many ways a repeat of a quarter earlier — only this time the numbers were worse with currency woes cutting further into international sales, profitability and now the company’s outlook on the coming […]
The U.S. Senate, following last month’s bipartisan action by the U.S. House of Representatives, tonight overwhelmingly passed a repeal of Medicare’s controversial sustainable growth rate formula. The vote, by a whopping 92-8 vote in the Senate, will avert a 21 percent cut in Medicare payments to doctors while at the same time moving future reimbursement […]
Italian billionaire Stefano Pessina wasn’t ready this week to say Walgreens Boots Alliance (WBA) was prepared to buy Rite Aid (RAD), but he said more government influence on payments to pharmacies could spur rapid consolidation in the U.S. Now the top executive at Walgreens, Pessina speaks from experience having run Alliance Boots pharmacies in Europe […]
Large-scale health data breaches reported by doctors and health plans have been rising steadily, a new report shows. From 2010 to 2013, nearly 1000 large breaches affected more than 29 million individual health records, and more than half resulted from theft or loss of laptops, thumb drives and paper records, according to researchers with access […]
April 14, 2015By Riley McDermid, BioSpace.com Breaking News Sr. Editor The American biotech sector will see a continued boom in its merger and acquisition cycle after an unprecedented first quarter saw over $100 billion in deals, with companies like Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG), and Biogen, Inc. all poised to participate, said UBS […]